An estimated one million Americans are living with Parkinson’s disease and approximately 60,000 new cases are diagnosed every year, a number that does not reflect the thousands of cases each year that go undetected. In addition, only 4% of people with Parkinson’s disease are diagnosed before the age of 50, which represents a significant area of need in clinical practice. Unfortunately, there is no cure for Parkinson’s disease; treatment is generally designed to treat symptoms. However, since it is a chronic and progressive disease that persists over a long period of time, symptoms will inevitably grow worse, and some patients will become severely disabled. No one can predict which symptoms will affect which patient, nor can they predict the severity of symptoms. This makes both short- and long-term management of Parkinson’s disease particularly difficult for clinicians.
As the baby-boom generation continues to grow older, the prevalence of Parkinson’s disease will likely increase accordingly. As a result, symptom recognition, early detection, and prompt referral to neurologic specialists are becoming increasingly important. A clearer understanding of treatment options – from levodopa to adjuncts to combination therapy – can also help ensure that patients are offered the most sound and individualized options for their own personal cases. The goals of this Parkinson’s disease program are threefold: (1) to help clinicians recognize early subtle symptoms associated with Parkinson’s disease in order to improve early diagnosis; (2) encourage clinicians to initiate individualized treatment plans in order to delay disease progression; and (3) incorporate clinical practice guidelines into practice in order to improve diagnosis and treatment. Our program will aim to address several gaps in the clinical management of Parkinson’s disease in order to improve clinician competence and performance, and enhance their current level of Parkinson’s disease care.
After completion of this activity, participant should be able to:
- Recognize the subtle symptoms associated with Parkinson’s Disease in order to improve early diagnosis
- Initiate individual treatment plans for patients with Parkinson’s Disease in order to delay disease progression
- Incorporate clinical practice guidelines for the diagnosis and treatment of patients with Parkinson’s Disease in order to optimize management
- Compare the benefits and risks of available treatment options for the patients with Parkinson’s Disease including adjust treatment strategies in order to individualize treatment plans
This activity has been designed to meet the educational needs of neurologists, movement disorder specialists, nurse practitioners, physician assistants, and other healthcare providers who manage patients with Parkinson’s Disease.
Fernando L. Pagán, MD
Associate Professor of Neurology
Department of Neurology
Director of Movement Disorders Program
Georgetown University Hospital
Mark J. Klafter, DO
University of Central Florida
President & Senior Partner
Neurological Services of Orlando, P.A.
M. Susan Burke, MD, FACP
Clinical Assistant Professor, Internal Medicine
Thomas Jefferson University Medical School
Internal Medicine Clinical Care Center Lankenau Hospital
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Fernando L. Pagán, MD
Disclosure: Dr. Pagán receives Consulting Fees from Medtronic, Inc., Merz Pharmaceuticals LLC, Teva Pharmaceuticals, US WorldMeds, LLC. He is on the Speakers’ Bureau for Avanir Pharmaceuticals, GlaxoSmithKline, Medtronic, Inc., Mertz Pharmaceuticals LLC, Novartis Corporation, Teva Pharmaceuticals, US WorldMeds, LLC. He has received Research Funds from Medtronic, Inc., and Teva Pharmaceuticals..
Mark J. Klafter, DO
Disclosure: Dr. Klafter is on the Speakers’ Bureaus for Allergan, Inc., Impax Pharmaceuticals, and Teva Pharmaceuticals.
M. Susan Burke, MD, FACP
Disclosure: Dr. Burke is on the Speakers’ Bureau for Merck & Co., Inc. Dr. Burke also receives consulting fees from Iroko Pharmaceuticals. .
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Matthew Frese of Med Learning Group has no relevant financial relationships to disclose.
Kelly Kraines of Med Learning Group has no relevant financial relationships to disclose.
Christopher Drury of The Quill Consulting has no relevant financial relationships to disclose.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTMed Learning Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- You must score 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
This CME activity was planned and produced in accordance with the ACCME Essentials. For CME questions, please contact: Med Learning Group at firstname.lastname@example.org Contact this CME provider for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/?page_id=865
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
DISCLOSURE OF UNLABLED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
COURSE VIEWING REQUIREMENTS
Internet Explorer (v6 or greater), or Firefox
Release Date: April 15, 2013
Expiration Date: April 14, 2014
This activity is supported by an educational grant from Teva Pharmaceuticals.
If you have any questions regarding this activity, send an email to email@example.com.
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields.
Copyright © 2013 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.